(March 1, 2018, 1:57 PM EST) -- ALEXANDRIA, Va. — Patent claims covering a method of treating pain by administering a tablet that provides a dosage form for twice-daily extended release administration of oxycodone “cannot stand,” a petitioner for inter partes review (IPR) told the Patent Trial and Appeal Board on Feb. 28 (Kashiv Pharma LLC v. Purdue Pharma L.P., et al., No. IPR2018-00717, PTAB)....